These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 25564062)

  • 1. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
    Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
    Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
    Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
    Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
    Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
    Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A retrospective analysis of clinic-pathological characteristics and prognostic factor for 137 cases of breast cancer brain metastasis].
    Gao YC; Liu H; Lu S; Zhuang XR; Wang YX; Wang T; Wu YY; Chen MX
    Zhonghua Wai Ke Za Zhi; 2013 Jan; 51(1):30-4. PubMed ID: 23578424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtypes and survival in patients with brain metastases.
    Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
    Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort.
    Jeon W; Jang BS; Jeon SH; Kim JH; Kim YJ; Kim SH; Kim CY; Han JH; Kim IA
    Breast J; 2018 Nov; 24(6):920-926. PubMed ID: 30596408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
    Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metastases free survival differs between breast cancer subtypes.
    Berghoff A; Bago-Horvath Z; De Vries C; Dubsky P; Pluschnig U; Rudas M; Rottenfusser A; Knauer M; Eiter H; Fitzal F; Dieckmann K; Mader RM; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
    Br J Cancer; 2012 Jan; 106(3):440-6. PubMed ID: 22233926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer.
    Sperduto PW; Kased N; Roberge D; Chao ST; Shanley R; Luo X; Sneed PK; Suh J; Weil RJ; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
    J Neurooncol; 2013 May; 112(3):467-72. PubMed ID: 23462853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
    Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
    Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
    Eichler AF; Kuter I; Ryan P; Schapira L; Younger J; Henson JW
    Cancer; 2008 Jun; 112(11):2359-67. PubMed ID: 18361426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study.
    Simsek M; Aliyev A; Baydas T; Besiroglu M; Demir T; Shbair AT; Seker M; Turk HM
    Breast J; 2022; 2022():5763810. PubMed ID: 36051468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.